<DOC>
	<DOCNO>NCT00875654</DOCNO>
	<brief_summary>The main objective study evaluate feasibility tolerance intravenous injection autologous mesenchymal stem cell patient present ischemic stroke ( le 6 week ) .</brief_summary>
	<brief_title>Intravenous Stem Cells After Ischemic Stroke</brief_title>
	<detailed_description>Stroke lead cause acquire adult disability . Except hospitalization stroke unit , thrombolysis show efficient treat acute ischemic stroke first three hour onset . Increasing brain plasticity stroke represent important alternative strategy . Cell therapy provide functional improvement cerebral ischemia rodent model . This `` restorative '' therapy aim replace destroyed cerebral tissue stem cell graft . Despite encouraging experiment , know yet best way administration stem cell , best dose optimal delay graft . The pioneer clinical study fail reproduce benefit patient probably limit number study patient . Therefore , translational study need improve knowledge promising field . Among different cell source , mesenchymal ( stromal ) stem cell ( MSC ) derive bone marrow offer advantage arise non tumoral modify source source immunological ethical problem . Our research project involve development cell therapy phase IIa clinical trial feasibility safety patient ( randomise , control , open , 3 parallel group ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<criteria>right leave carotid ischemic stroke 14 previous day , confirm MRI . Persistent neurological deficit ( NIHSS &gt; =7 ) . Optimal medical treatment ( antithrombotics , antihypertensive , statin ) . General state compatible program functional rehabilitation . Severe extensive stroke imply vital prognosis . Severe persistent neurological deficit ( NIHSS &gt; 24 ) . Medical history neurological pathology deficit consequence ( Rankin &lt; 3 stroke ) . Serious psychiatric disease . Myocardial infarction less 3 month old . Recurring thromboembolic disease less 6 month old . Patient organ transplantation . Medical history infection ( HIV , HTLV , HBV , HCV ) . Current immunosuppressive/immunomodulating treatment . Medical history cancer . Medical history chemotherapy . Known chronic kidney failure ( clearance creatinin &lt; 90 ml/min/1,73m2 ) . Known hepatic failure ( diminution prothrombin level ( TP ) corrigiable vitamin K ) . Obesity hinding bonemarrow sample iliac crest . Pathology imply vital prognosis 3 month follow stroke . Refusal participate . Patient unable give personally his/her consent . Pregnant , parturient feed woman . Woman age procreate could receive effective method contraception study . Participation another therapeutic clinical trial period exclusion therapeutic clinical study . Privation liberty decision justice administration , legal protection . Non affiliation social security .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Cell therapy</keyword>
	<keyword>Stroke</keyword>
	<keyword>Neuronal Plasticity</keyword>
	<keyword>Recovery</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Transplantation</keyword>
</DOC>